Iroko Pharmaceuticals has announced positive results from its Phase III study of investigational, lower dose submicron indomethacin to treat post-surgical acute pain.

The study demonstrated significant pain relief compared with placebo, meeting the primary endpoint.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Iroko Pharmaceuticals chief medical officer Dr Clarence Young said; "These top line results lend further support to our novel approach to developing new NSAID formulations that may be able to do more with less, a concept that could represent a significant new development in the area of pain management."

"The study demonstrated significant pain relief compared with placebo, meeting the primary endpoint."

A total of 462 patients were randomised to receive submicron indomethacin (40mg twice or three times daily, or 20mg three times daily), celecoxib (400mg loading dose, 200mg twice daily) or placebo in the multicentre study of lower dose submicron indomethacin.

According to the study data, all doses of submicron indomethacin met the primary objective of showing considerable improvement in pain relief, as measured by the combined differences in pain intensity assessed at intervals over 48 hours using a visual analog scale (VASSPID-48).

See Also:

Iroko Pharmaceuticals president and CEO John Vavricka said the company’s multiple lower dose submicron NSAID programs are designed to apply scientific innovation to pain management, offering patients and physicians much needed options.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Data from this study, together with positive results announced earlier this year from our Phase III study of lower dose submicron diclofenac in acute pain, add further momentum to Iroko’s goal of leading meaningful progress in this underserved therapeutic area," Vavricka said.